New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - 10 mcg/0.5ml - active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenoxyethanol sodium chloride thiomersal water for injection active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - engerix-b is indicated for active immunization against hepatitis b virus infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - 20 mcg/ml - active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenoxyethanol sodium chloride thiomersal water for injection active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - engerix-b is indicated for active immunization against hepatitis b virus infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)); influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)); influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) - suspension for injection - active: influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)) influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)) influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) excipient: commercial light duty detergent d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate formaldehyde gentamicin sulfate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium deoxycholate sucrose water for injection - fluarix is indicated for prophylaxis against influenza in adults and children older than six months of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml;  ; hepatitis a vaccine 1440 eu/ml - suspension for injection - 1440 eu/ml - active: hepatitis a vaccine 1440 eu/ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml;  ; hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml - suspension for injection - 720 elisa u/0.5ml - active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)); vi capsular polysaccharide of s. typhi ty2 25 µg/ml;   - suspension for injection - active: hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)) vi capsular polysaccharide of s. typhi ty2 25 µg/ml   excipient: aluminium hydroxide amino acids formaldehyde neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - hepatyrix is indicated for active immunisation of adults and adolescents older than 15 years of age at risk of both hepatitis a virus infection and typhoid fever. immunisation with hepatyrix is particularly recommended in subjects who are, or will be, at increased risk of infection such as travellers from countries of low endemicity to areas where the prevalence of hepatitis a and typhoid fever is high.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu]; pertactin 8ug;  ; pertussis filamentous haemagglutinin 25ug;  ; pertussis toxoid, adsorbed 25ug;  ; tetanus toxoid, adsorbed 40 [iu]; diphtheria toxoid, adsorbed 30 [iu]; pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid, adsorbed 40 [iu] - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 30 [iu] pertactin 8ug   pertussis filamentous haemagglutinin 25ug   pertussis toxoid, adsorbed 25ug   tetanus toxoid, adsorbed 40 [iu] excipient: aluminium as aluminium hydroxide & phosphate sodium chloride water for injection active: diphtheria toxoid, adsorbed 30 [iu] pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid, adsorbed 40 [iu] excipient: aluminium as aluminium hydroxide & phosphate phenoxyethanol polysorbate 80 sodium chloride water for injection - infanrix (dtpa) is indicated for active primary immunisation against diptheria, tetanus and pertussis. infanrix is indicated as fourth and/or fifth dose for children from 15 months of age up to and including 6 years of age who have previously been immunised with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccine.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 60 iu/ml; pertactin 16 µg/ml;  ; pertussis filamentous haemagglutinin 50 µg/ml;  ; pertussis toxoid, adsorbed 50 µg/ml;  ; polio virus type 1 80 dagu/ml;  ; polio virus type 2 16 dagu/ml;  ; polio virus type 3 64 dagu/ml;  ; tetanus toxoid, adsorbed 80 iu/ml - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 60 iu/ml pertactin 16 µg/ml   pertussis filamentous haemagglutinin 50 µg/ml   pertussis toxoid, adsorbed 50 µg/ml   polio virus type 1 80 dagu/ml   polio virus type 2 16 dagu/ml   polio virus type 3 64 dagu/ml   tetanus toxoid, adsorbed 80 iu/ml excipient: aluminium hydroxide neomycin sulfate polymyxin b sulfate sodium chloride water for injection - infanrix®-ipv is indicated for active primary immunisation against diphtheria, tetanus, pertussis, and poliomyelitis. infanrix®-ipv is also indicated as a booster dose for children who have previously been immunised with dtp and polio antigens.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - measles vaccine, schwarz strain 1000 ccid50 (not less than); mumps virus, live attenuated, rit 4385 5012 ccid50 (not less than);  ; rubella virus, wistar ra27/3 strain 1000 ccid50 (not less than) - powder for injection with diluent - 0.5 ml - active: measles vaccine, schwarz strain 1000 ccid50 (not less than) mumps virus, live attenuated, rit 4385 5012 ccid50 (not less than)   rubella virus, wistar ra27/3 strain 1000 ccid50 (not less than) excipient: amino acids lactose mannitol sorbitol water for injection - priorix is indicated for the active immunisation against measles, mumps and rubella.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) - powder with diluent for oral suspension - 1e+006 ccid50 - active: rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) excipient: amino acids dextran 40 dulbecco's modified eagle medium sorbitol sucrose calcium carbonate water for injection xanthan gum - rotarix is indicated for the prevention of rotavirus gastroenteritis